Royal Bank of Canada
ALXN

Royal Bank of Canada’s Alexion Pharmaceuticals ALXN Stock Holding History

Royal Bank of Canada’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-831,958
Closed -$153M – 8179
2021
Q2 		$153M Buy
831,958
+577,678
+227% +$99.2M 0.04% 371
2021
Q1 		$38.9M Buy
254,280
+11,668
+5% +$1.8M 0.01% 829
2020
Q4 		$37.9M Buy
242,612
+116,578
+92% +$15M 0.01% 830
2020
Q3 		$14.4M Buy
126,034
+68,586
+119% +$7.4M 0.01% 1298
2020
Q2 		$6.45M Buy
57,448
+14,132
+33% +$1.5M ﹤0.01% 1768
2020
Q1 		$3.89M Sell
43,316
-61,358
-59% -$6.02M ﹤0.01% 1992
2019
Q4 		$11.3M Sell
104,674
-8,362
-7% -$894K ﹤0.01% 1553
2019
Q3 		$11.1M Sell
113,036
-32,104
-22% -$3.62M ﹤0.01% 1494
2019
Q2 		$19M Buy
145,140
+17,659
+14% +$2.28M 0.01% 1126
2019
Q1 		$17.2M Buy
127,481
+5,324
+4% +$662K 0.01% 1173
2018
Q4 		$11.9M Buy
122,157
+13,421
+12% +$1.59M 0.01% 1334
2018
Q3 		$15.1M Buy
108,736
+31,221
+40% +$3.92M 0.01% 1321
2018
Q2 		$9.62M Sell
77,515
-57,258
-42% -$6.69M ﹤0.01% 1565
2018
Q1 		$15M Buy
134,773
+17,291
+15% +$2.07M 0.01% 1279
2017
Q4 		$14.1M Sell
117,482
-30,558
-21% -$3.72M 0.01% 1378
2017
Q3 		$20.8M Buy
148,040
+25,356
+21% +$3.44M 0.01% 1059
2017
Q2 		$14.9M Sell
122,684
-61,091
-33% -$7.11M 0.01% 1250
2017
Q1 		$22.3M Buy
183,775
+798
+0.4% +$103K 0.01% 952
2016
Q4 		$22.4M Buy
182,977
+23,778
+15% +$2.91M 0.01% 993
2016
Q3 		$19.5M Buy
159,199
+53,054
+50% +$6.83M 0.01% 1029
2016
Q2 		$12.4M Buy
106,145
+6,594
+7% +$936K 0.01% 1307
2016
Q1 		$13.9M Sell
99,551
-44,837
-31% -$6.58M 0.01% 1175
2015
Q4 		$27.5M Buy
144,388
+73,702
+104% +$12.9M 0.02% 751
2015
Q3 		$11.1M Sell
70,686
-49,541
-41% -$9.04M 0.01% 1094
2015
Q2 		$21.7M Buy
120,227
+75,148
+167% +$13M 0.02% 772
2015
Q1 		$7.81M Sell
45,079
-71,269
-61% -$12.9M 0.01% 1336
2014
Q4 		$21.5M Buy
116,348
+35,423
+44% +$6.56M 0.01% 817
2014
Q3 		$13.4M Buy
80,925
+17,934
+28% +$2.95M 0.01% 1047
2014
Q2 		$9.84M Sell
62,991
-44,895
-42% -$7.09M 0.01% 1233
2014
Q1 		$16.4M Sell
107,886
-89,841
-45% -$14.3M 0.01% 856
2013
Q4 		$26.3M Buy
197,727
+34,584
+21% +$4.15M 0.02% 651
2013
Q3 		$18.9M Buy
163,143
+48,336
+42% +$5.3M 0.01% 761
2013
Q2 		$10.6M Buy
+114,807
New +$11.1M 0.01% 1009

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Royal Bank of Canada's ALXN Position: Q3 2021 in Review

Royal Bank of Canada sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 831,958 shares — an estimated $153M sold.

Royal Bank of Canada first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $153M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Royal Bank of Canada reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Royal Bank of Canada sold 831,958 Alexion Pharmaceuticals shares in Q3 2021, an estimated $153M.
  • Royal Bank of Canada first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Royal Bank of Canada's Alexion Pharmaceuticals position peaked at $153M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Royal Bank of Canada's 13F filing for Q3 2021, filed 15 Nov 2021.